 |
|
Study reveals 2 genes linked to disabling arthritis
October 22, 2007Genome scan also confirms association of two genes implicated in Graves' disease
SEATTLE - An international team of researchers led by a Fred Hutchinson Cancer Research Center geneticist has discovered two genes linked to a disabling form of arthritis called ankylosing spondylitis, a painful and progressive disease in which some or all of the spine's vertebrae fuse together. The researchers also validated the association of two genes implicated in Graves' disease, an autoimmune condition that causes overactivity of the thyroid gland.
Principal investigator and corresponding author Lon Cardon, Ph.D., and colleagues in the U.K.-based Wellcome Trust Case Control Consortium and The Australo-Anglo-American Spondylitis Consortium reported their findings online Oct. 21 in Nature Genetics.
The study revealed two genes linked to ankylosing spondylitis: ARTS1 and IL23R, both of which influence immune function. Together with the previously known gene HLA-B27, the new findings increase to three the number of genes known to be involved in the disease. A person who carries all three genetic variants would be expected to have a one-in-four chance of developing the disease.
The discovery of both genes, as well as the validation of two prime genetic suspects in Graves' disease - genes known as TSHR and FCRL3 - arose from a comprehensive scan of the human genome in which dozens of researchers used genotyping technology to analyze DNA samples from thousands of patients suffering from a variety of common diseases and compared them to DNA from a similar number of healthy control subjects.
In addition to Graves' disease and ankylosing spondylitis, the study mined for common genetic variations associated with multiple sclerosis and breast cancer. The most significant findings, however, were in ankylosing spondylitis, a type of arthritis that not only affects the spine but also can attack other joints and organs, including the heart, lungs and eyes. The condition afflicts an estimated one in 200 males and one in 500 females and typically strikes during adolescence and young adulthood.
Previous research also has linked IL23R with inflammatory-bowel disease (Crohn's disease) and psoriasis. "Clinically these diseases tend to occur together - people with inflammatory-bowel disease also tend to have a higher probability of having ankylosing spondylitis and psoriasis. The IL23R gene provides a genetic link that sheds new light on their co-occurrence," said Cardon, a member of the Hutchinson Center's Human Biology Division.
With these new clues in hand, researchers next will study the genes in model organisms to work out the pathways by which they cause disease. The ultimate goal is improved diagnostics and drug discovery. For example, knowing that genetic variation in IL23R is a risk factor for both Crohn's disease and ankylosing spondylitis suggests that drugs being tested for one also may be effective against the other.
"We already knew that IL23R is involved in inflammation, but no one had ever thought it was involved in ankylosing spondylitis," said Matthew Brown, M.D., a clinical researcher from the Wellcome Trust Centre for Human Genetics at the University of Oxford, who co-led the study with Cardon. A treatment for Crohn's disease that inhibits the activity of this gene already is undergoing human trials, Brown said, and the drug also looks very promising as a potential treatment for ankylosing spondylitis.
"This is an exciting time for genetics. The Wellcome Trust Case Consortium has yielded more genetic discoveries for common diseases in 2007 than have been made in the entire history of the field," said Cardon, a statistical methodologist who last year came to the Hutchinson Center's Human Biology Division from the University of Oxford, where he conducted the research and retains an academic post.
"Seattle is very, very strong in epidemiology and genetics and has a worldwide reputation in biostatistics - that's what brought me here," said Cardon, also a professor of biostatistics at the University of Washington.
Fred Hutchinson Cancer Research Center
The study revealed two genes linked to ankylosing spondylitis: ARTS1 and IL23R, both of which influence immune function. Together with the previously known gene HLA-B27, the new findings increase to three the number of genes known to be involved in the disease. A person who carries all three genetic variants would be expected to have a one-in-four chance of developing the disease.
The discovery of both genes, as well as the validation of two prime genetic suspects in Graves' disease - genes known as TSHR and FCRL3 - arose from a comprehensive scan of the human genome in which dozens of researchers used genotyping technology to analyze DNA samples from thousands of patients suffering from a variety of common diseases and compared them to DNA from a similar number of healthy control subjects.
In addition to Graves' disease and ankylosing spondylitis, the study mined for common genetic variations associated with multiple sclerosis and breast cancer. The most significant findings, however, were in ankylosing spondylitis, a type of arthritis that not only affects the spine but also can attack other joints and organs, including the heart, lungs and eyes. The condition afflicts an estimated one in 200 males and one in 500 females and typically strikes during adolescence and young adulthood.
Previous research also has linked IL23R with inflammatory-bowel disease (Crohn's disease) and psoriasis. "Clinically these diseases tend to occur together - people with inflammatory-bowel disease also tend to have a higher probability of having ankylosing spondylitis and psoriasis. The IL23R gene provides a genetic link that sheds new light on their co-occurrence," said Cardon, a member of the Hutchinson Center's Human Biology Division.
With these new clues in hand, researchers next will study the genes in model organisms to work out the pathways by which they cause disease. The ultimate goal is improved diagnostics and drug discovery. For example, knowing that genetic variation in IL23R is a risk factor for both Crohn's disease and ankylosing spondylitis suggests that drugs being tested for one also may be effective against the other.
"We already knew that IL23R is involved in inflammation, but no one had ever thought it was involved in ankylosing spondylitis," said Matthew Brown, M.D., a clinical researcher from the Wellcome Trust Centre for Human Genetics at the University of Oxford, who co-led the study with Cardon. A treatment for Crohn's disease that inhibits the activity of this gene already is undergoing human trials, Brown said, and the drug also looks very promising as a potential treatment for ankylosing spondylitis.
"This is an exciting time for genetics. The Wellcome Trust Case Consortium has yielded more genetic discoveries for common diseases in 2007 than have been made in the entire history of the field," said Cardon, a statistical methodologist who last year came to the Hutchinson Center's Human Biology Division from the University of Oxford, where he conducted the research and retains an academic post.
"Seattle is very, very strong in epidemiology and genetics and has a worldwide reputation in biostatistics - that's what brought me here," said Cardon, also a professor of biostatistics at the University of Washington.
Fred Hutchinson Cancer Research Center
Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News RSSCV risk management should be mandatory in RA and other types of inflammatory rheumatic disease
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk calculators should be adapted to the increased CV risk in inflammatory rheumatic disease patients.
New findings show Enbrel significantly reduced levels of C-reactive protein
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment.
Phase 3 data show golimumab improved psoriatic arthritis symptoms
Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease.
Golimumab significantly reduced signs and symptoms of ankylosing spondylitis
More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting.
Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Research funded by the Wellcome Trust and the Arthritis Research Campaign has identified two genes implicated in the disease ankylosing spondylitis, a common disease primarily causing back pain and progressive stiffness.
UT Rheumatologists Discover Two Genes
Work done in part by researchers at The University of Texas Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The findings are published in the Oct. 21 online edition of Nature Genetics, a journal that emphasizes research on the genetic basis for common and complex diseases.
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC).
Largest ever study of genetics of common diseases published today
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, today publishes its results in the journals Nature and Nature Genetics.
Monoclonal antibody reduces exacerbations in asthmatics
Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.
NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
The UK National Institute for Health and Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult patients with severe plaque psoriasis.
More Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News Articles
 | Ankylosing Spondylitis: The Facts (The Facts Series) by Muhammad Asim Khan Ankylosing spondilitis is a chronic form of arthritis known to affect around 1 in 200 people(over 1 million sufferers in the USA alone). Ankylosing spondilitis: the facts is the first mass market book to be published on this important disease written by someone who is not only a leading expert on AS, but is affected by it... |
 | Ankylosing Spondylitis (Fast Facts) by Maxime Dougados, Desiree, M.D. van der Heijde Ankylosing Spondylitis is an insidious disease that is often difficult to diagnose in the early stages but can cause progressive and sometimes severe disability. This handbook, written by international experts, clearly describes the features of ankylosing spondylitis and emphasizes the importance of accurate assessment. It then discusses the evidence regarding the evidence regarding the efficiacy... |
| Ankylosing Spondylitis (Oxford American Respiratory Library) by Muhammad Asim Khan Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical... | |
 | 21st Century Complete Medical Guide to Ankylosing Spondylitis, Authoritative CDC, NIH, and FDA Documents, Clinical References, and Practical Information for Patients and Physicians (CD-ROM) by PM Medical Health News This up-to-date electronic book on CD-ROM provides the best collection available anywhere of official Federal government information and documents on the subject of Ankylosing Spondylitis (AS). This CD-ROM uses next-generation search technology that allows complete indexing and makes all files on the disc fully searchable. For patients, practical information is provided in clearly written patient... |
 | Ankylosing Spondylitis and the Spondyloarthropathies: A Companion to Rheumatology 3E by Michael H. Weisman, John D. Reveille, Desiree van der Heijde Developed as a companion text to the 3rd Edition of the heralded Rheumatology, by Hochberg et al., this state-of-the-art reference presents today's understanding of the spondylarthropathies. You'll find thorough examinations of the innovative, new treatments that challenge older concepts of treatment and management of the disease. Noted experts in the field also present the latest concepts in... |
 | Ankylosing Spondylitis: Diagnosis and Management The first and only interdisciplinary guide dedicated to the subject, this reference leads readers through the pathogenic, genetic, clinical, and biomechanical aspects of ankylosing spondylitis (AS). It also addresses issues related to outcomes assessment, medical treatment, surgical complications, disease management, and genetics. Detailing current treatment options and clinical essentials, this... |
 | Ankylosing Spondylitis Medical Guide by Qontro Medical Guides The Ankylosing Spondylitis Medical Guide is a publication which has been designed to better help readers understand Ankylosing Spondylitis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Ankylosing Spondylitis. The Ankylosing Spondylitis Medical Guide is highly recommended for those... |
 | Ankylosing Spondylitis - A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers by Philip M. Parker In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.... |
| Ankylosing spondylitis: Discussions in patient management by Andrei Calin | |
| ANKYLOSING SPONDYLITIS: A PORTRAIT SURVEY. (SIGNED). |
| © 2009 BrightSurf.com |